4C-T-2, also known as 2,5-dimethoxy-4-ethylthio-ñ-ethylphenethylamine, is a synthetic drug of the phenethylamine, phenylisobutylamine, and 4C families. It is the ñ-ethylated analogue of 2C-T-2.
4C-T-2 acts as a serotonin 5-HT<sub>2</sub> receptor agonist, including of the serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors.
4C-T-2 was first described in the scientific literature by at least 2005. It was more fully characterized in 2010 and then in 2023.